Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease, and the current pharmacological treatment for DKD is limited to renin-angiotensin system (RAS) inhibitors. Adenosine is detectable in the kidney and is significantly elevated in response to cellular damage. While all 4 known subtypes of adenosine receptors, namely, A 1 AR, A 2a AR, A 2b AR, and A 3 AR, are expressed in the kidney, our previous study has demonstrated that a novel, orally active, species-independent, and selective A 3 AR antagonist, LJ-1888, ameliorates unilateral ureteral obstructioninduced tubulointerstitial fibrosis. The present study examined the protective effects of LJ-2698, which has higher affinity and selectivity for A 3 AR than LJ-1888, on DKD. In experiment I, dose-dependent effects of LJ-2698 were examined by orally administering 1.5, 5, or 10 mg/kg for 12 weeks to 8-week-old db/db mice. In experiment II, the effects of LJ-2698 (10 mg/kg) were compared to those of losartan (1.5 mg/kg), which is a standard treatment for patients with DKD. LJ-2698 effectively prevented kidney injuries such as albuminuria, glomerular hypertrophy, tubular injury, podocyte injury, fibrosis, inflammation, and oxidative stress in diabetic mice as much as losartan. In addition, inhibition of lipid accumulation along with increases in PGC1α, a master regulator of mitochondrial biogenesis, were demonstrated in diabetic mice treated with either LJ-2698 or losartan. These results suggest that LJ-2698, a selective A 3 AR antagonist, may become a novel therapeutic agent against DKD.
Introduction
Diabetic kidney disease (DKD) is emerging as a worldwide public health problem and is an independent risk factor for cardiovascular morbidity and mortality 1 . DKD affects up to 30-40% of diabetic patients and has been recognized as a major cause of end-stage kidney disease (ESKD) 2 . To date, angiotensin receptor blockers (ARBs) and angiotensin converting enzyme (ACE) inhibitors are the mainstay therapeutic options for preventing the progression of DKD. However, those drugs show limitations in delaying the onset of ESKD 3 . It is therefore imperative to find alternative targets in halting the disease progression. Thus, the present study is focused on gaining better insight into LJ-2698, which is a new A 3 adenosine receptor (A 3 AR) antagonist, in ameliorating DKD progression.
Adenosine is a metabolic breakdown product of adenosine triphosphate (ATP) and contributes to cytoprotection under stress, such as ischemia, hypoxia, and inflammation 4 . In fact, renal adenosine concentrations increase significantly in states of high renal ATP consumption, such as hypoxia and perfusion impairment 5 . Recent metabolomic studies have revealed a significant elevation of plasma adenosine and its derived metabolites in patients with DKD 6, 7 . However, the role of adenosine in diabetic kidney remains elusive.
The regulation of tissue function by adenosine is mediated through activation of a G-protein coupled receptor (GPCR) family, consisting of A 1 , A 2a , A 2b , and A 3 adenosine receptors (ARs) 8 . The A 3 AR is ubiquitously expressed in various tissues 9 . Interestingly, experimental diabetic rats 10 and diabetic patient biopsies 11 demonstrated that A 3 AR expression was up-regulated in diabetic kidneys and positively correlated with disease progression. Thus, targeting A 3 AR may offer a therapeutic benefit in DKD. Renoprotective effects of an A 3 AR antagonist have been reported in several kidney injury models, such as ischemiareperfusion injury 12 , myoglobinuria-induced injury 13 , adriamycin-induced nephropathy 14 and unilateral ureteral obstruction (UUO)-induced interstitial fibrosis 15 . Furthermore, a recent study reported a correlation between increased plasma concentration of adenosine and markers of renal fibrosis in diabetic rats, which were remarkably reduced by the administration of an A 3 AR antagonist 11 .
The present study investigated a newly developed A 3 AR antagonist, LJ-2698, which is a potent, highly selective, species-independent, and orally active agent with higher binding affinity to human A 3 AR than its analog, LJ-1888 16 . In the first step, dose-dependent effects of LJ-2698 were tested (at doses of 1.5, 5, or 10 mg/kg) in db/db mice, which is a model of type 2 diabetes mellitus (T2DM). Among the 3 dosage regimens, 10 mg/kg presented significant effects in ameliorating kidney injury. Then, we compared the efficacy of LJ-2698 in ameliorating DKD with that of losartan, which is a well-established clinical drug in preventing the aggravation of DKD.
Materials and methods

Chemicals and reagents
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated.
Experiment I, Dose-dependent preventive effects of LJ-2698
All animal experiments were conducted according to the Institutional Animal Care and Use Committee of Ewha Laboratory Animal Genomics Center (IACUC-14-109). Eight-week-old male C57BLKS/J-db/db and agematched control C57BLKS/J-m + /db mice (Japan SLC Inc., Hamamatsu, Japan) were housed in a room maintained at 22 ± 2℃ with a 12 h dark/12 h light cycle. To examine the preventive effects of LJ-2698 in a dosedependent manner, LJ-2698 (1.5, 5, or 10 mg/kg) or 0.25% carboxymethyl cellulose (CMC) was administered daily to diabetic mice for 12 weeks by oral gavage. The control db/m group was administered an equal volume of CMC.
Experiment II, Renoprotective effects of LJ-2698 compared with losartan
LJ-2698 (10 mg/kg) or CMC was administered daily to control and diabetic mice for 12 weeks by oral gavage. Losartan (1.5 mg/kg) was administered in diabetic mice to compare with the effects of LJ-2698. Twelve weeks after administration, all mice were sacrificed.
Measurement of blood parameters
Before sacrificing the mice, blood samples were collected. The hemoglobin A1c (HbA1c) level was determined by a DCA2000 HbA1c reagent kit (SIEMENS Healthcare Diagnostics, Inc., Tarrytown, NY, USA). Blood glucose was measured with a glucometer (OneTouch Ultra, Johnson & Johnson Co., CA, USA). Then, blood samples were centrifuged at 3000 rpm for 15 min at 4°C and plasma was collected. Plasma cystatin C was measured by ELISA Kits (R&D Systems, Minneapolis, MN, USA).
Measurement of urine parameters
Before sacrificing the mice, urine samples were collected in a metabolic cage for 24 h and centrifuged at 3000 rpm for 10 min. Urinary albumin excretion was measured by ELISA Kits (ALPCO, Westlake, OH, USA). The levels of urinary lipid peroxides (LPO) were measured by the thiobarbituric acid method. Urinary KIM-1 was measured by ELISA Kits (R&D Systems, Minneapolis, MN, USA).
Histology and immunohistochemistry
The right kidney was fixed with 2% paraformaldehydelysine-periodate (pH 7.4), dehydrated, embedded in paraffin, and sectioned. Sections were stained with periodic acid-Schiff (PAS) reagent. On each section, 15 different superficial glomeruli were randomly selected from each kidney to analyze glomerular volume and fractional mesangial area (FMA). Paraffin-embedded sections were stained using picrosirius red stain to demonstrate collagen matrix. For immunohistochemistry (IHC), anti-nephrin (PROGEN Biotechnik GmbH Inc., Heidelberg, Germany, 1:100), anti-F4/80, and anti-8-oxo-dG (Santa Cruz Biotechnology, CA, USA, 1:400) antibodies were used. Images were obtained using a Zeiss microscope equipped with an Axio Cam HRC digital camera and Axio Cam software (Carl Zeiss, Thornwood, NY, USA) and quantified by Image-Pro Plus 4.5 software (Cybernetics, Silver Spring, MD, USA).
Oxidative stress in the kidney
The extent of oxidative stress in kidney tissue was determined through measurement of LPO level utilizing the redox reaction with ferrous ion. Cayman's Lipid Hydroperoxide Assay Kit was used for this measurement (Cayman Chemical Co, Ann Arbor, MI, USA).
Lipid accumulation
Lipid accumulation was detected by Oil Red O (ORO) staining on kidney sections. Fixed tissues were washed and incubated with 0.7% ORO for 10 min. After the samples were washed with distilled water, images were captured with a Zeiss microscope equipped with an Axio Cam HRC digital camera and Axio Cam software (Carl Zeiss, Thornwood, NY, USA).
Western blot
The protein concentration in kidney tissue homogenates was measured by the bicinchoninic acid method (Pierce Pharmaceuticals). For western blotting, protein was electrophoresed on a 10% SDS-PAGE mini-gel and transferred onto a polyvinylidene difluoride (PVDF) membrane. PVDF membranes were incubated overnight at 4°C in primary antibody, such as anti-A 1 AR (1:500; Membranes were subsequently incubated with horseradish peroxidase-conjugated secondary antibody (1:1000 dilution) for 60 min at room temperature. Specific signals were detected using an enhanced chemiluminescence method (Amersham, Buckinghamshire, UK).
Real-time quantitative reverse transcription PCR (qRT-PCR)
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Expression of mRNAs was measured by real-time qRT-PCR using the ABI7300 (Applied Biosystems, Carlsbad, CA, USA) with a 20 μL reaction volume consisting of cDNA transcripts, primer pairs, and SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, CA, USA). Primer sequences are listed in Table 1 . 18 S and β-actin were used as an internal control to normalize the genes.
Statistical analysis
Results were expressed as the mean ± SE. ANOVA was used to assess differences between multiple groups followed by Fisher post hoc analysis. The level of statistical significance was set at a p-value less than 0.05.
Results
Physical and biochemical characteristics of experimental animals
The physical and biochemical characteristics for each experimental group are presented in Tables 2 and 3 for experiments I and II, respectively. Diabetic db/db mice showed significantly higher body weight, blood glucose, HbA1c, and urine volume than non-diabetic db/m mice. Neither LJ-2698 nor losartan affected blood glucose, HbA1C, or body weight in db/db mice.
db/db Mice presents higher expression of renal A 3 AR than db/m mice
The expressions of all AR subtypes were initially measured in order to determine which AR subtype was significantly increased in diabetic conditions. Analysis of kidney homogenates from 20-week-old mice showed similar protein and mRNA expression levels of A 1 AR, Fig. 1a, b ).
LJ -2698 improves kidney morphology in db/db mice
To examine the effects of LJ-2698 on diabetic glomerular morphology, kidney sections were stained with PAS staining (Fig. 2a ). Twenty-week-old db/db mice showed increased glomerular volume and FMA, which were effectively prevented by 12 weeks of treatment with LJ-2698 at the 3 different doses (1.5, 5, or 10 mg/kg). The reduction in glomerular volume and FMA in db/db mice was not significantly different among the 3 different doses of LJ-2698 ( Fig. 2b, c) .
LJ-2698 exhibits renoprotective effects in a dosedependent manner in db/db mice Next, we measured kidney injury indexes to confirm the most effective concentration of LJ-2698. Urinary albumin excretion was increased in db/db mice and was significantly reduced following 5 and 10 mg/kg treatment with LJ-2698 ( Fig. 3a) . Reduced nephrin and increased NGAL mRNA levels, which indicated podocyte and tubular injury in db/db mice, respectively, were effectively prevented by 10 mg/kg LJ-2698 treatment (Fig. 3b, c) .
TGF-β, collagen IV, and fibronectin mRNA levels were measured as fibrosis markers. Increased TGF-β in db/db mice was inhibited only in the 10 mg/kg treatment group (Fig. 3d ). Meanwhile, collagen IV and fibronectin mRNA levels were reduced by 5 and 10 mg/kg LJ-2698 treatment (Fig. 3e, f) .
MCP-1 and ICAM-1 mRNA were measured as inflammation markers. The elevated MCP-1 mRNA level in db/ mice was reduced by 5 and 10 mg/kg of LJ-2698, but the ICAM-1 mRNA level was reduced only by the highest dose, 10 mg/kg of LJ-2698 ( Fig. 3g, h) . Additionally, urinary excretion of LPO was monitored as an index of oxidative stress. Urinary LPO was markedly increased in the db/db control group and was significantly decreased after 12-week-LJ-2698 treatment in both 5 and 10 mg/kg treatment groups (Fig. 3i) .
Altogether, 10 mg/kg treatment with LJ-2698 offered sufficient effects in inhibiting the progression of kidney injury in db/db mice.
LJ-2698 prevents glomerular and tubular injury as much as losartan in db/db mice
To determine whether LJ-2698 has a comparable effect with the mainstay treatment of DKD, we compared the effects of 10 mg/kg of LJ-2698 with those of 1.5 mg/kg of losartan. LJ-2698 effectively reduced urinary albumin excretion in db/db mice as much as losartan (Fig. 4a ). Diabetic db/db mice showed significantly increased plasma cystatin C, which was decreased by either LJ-2698 or losartan (Fig. 4b) . However, increased urinary KIM-1 excretion in db/db mice was significantly prevented only by LJ-2698 treatment (Fig. 4c) .
The results of PAS staining (Fig. 4d ) demonstrated increased glomerular volume ( Fig. 4f ) and FMA (Fig. 4g ) in diabetic mice, which were significantly decreased by either LJ-2698 or losartan. Nephrin immuno-staining ( Fig. 4e) representing podocyte integrity was significantly reduced in db/db mice, which was effectively prevented by either LJ-2698 or losartan treatment (Fig. 4h) . Overall, LJ-2698 administration showed a comparable ability with losartan in ameliorating kidney injuries under diabetic conditions.
LJ-2698 inhibits kidney fibrosis in db/db mice
We further investigated the efficacy of LJ-2698 treatment in preventing the progressive accumulation of the extracellular matrix which leads to renal fibrosis. Elevated collagen IV, PAI-1, and TGF-β mRNA levels in db/db were significantly reduced by 12 weeks of treatment with either LJ-2698 or losartan (Fig. 5a-c) . Likewise, picrosirius red staining depicting collagen accumulation in the kidney was increased in db/db mice and was significantly prevented by either LJ-2698 or losartan treatment ( Fig. 5d, e ).
LJ-2698 ameliorates kidney inflammation in db/db mice
To determine whether LJ-2698 has an anti-inflammatory effect in diabetic kidneys, we evaluated the expression of proinflammatory markers in renal tissue. Elevated mRNA levels of MCP-1 and TNF-α in db/db mice were effectively suppressed by either LJ-2698 or losartan treatment (Fig. 6a, b) . Macrophage infiltration in the kidney, indicated by positive staining of F4/80, was markedly increased in db/db mice and significantly reduced by either LJ-2698 or losartan treatment (Fig. 6c, d) .
LJ-2698 prevents kidney oxidative stress in db/db mice
As oxidative stress plays a central role in the progression of kidney injury, we evaluated the state of oxidative stress in db/db mice through 8-oxo-dG immunostaining in kidney tissues and through the LPO assay in both kidney and urine samples. db/db mice presented increases in 8-oxo-dG expression and the LPO concentration in both kidney and urine samples, which were all significantly attenuated by LJ-2698 treatment. Losartan also decreased 8-oxo-dG expression and LPO concentration in the kidney but not the LPO concentration in the urine (Fig. 7a-d) .
LJ-2698 inhibits renal lipid accumulation in db/db mice db/db mice classically represent renal lipid accumulation that contributes to the progression of kidney injury. ORO staining revealed more lipid droplets accumulated in glomeruli and tubules of db/db mice than those of db/ m mice at 20 weeks old. Lipid droplets in the kidneys of db/db mice were significantly decreased by either LJ-2698 or losartan treatment (Fig. 8a, b) .
Renal PGC1α was decreased in db/db mice, which was significantly increased by either LJ-2698 or losartan treatment (Fig. 8c, d) . In parallel, treated diabetic mice demonstrated increases in transcription factors, such as PPARα (Fig. 8e ) and NRF1 (Fig. 8f ), which interacts with PGC1α. Furthermore, db/db mice treated with either LJ-2698 or losartan exhibited elevation in i) mitochondrial transcripts indicated by TFAM (Fig. 8g) , ii) oxidative phosphorylation indicated by COX4i1 (Fig. 8h, i) and Cytb (Fig. 8j) , and iii) fatty acid β-oxidation presented by CPT1α and MCAD (Fig. 8k, l) .
Discussion
Previous studies have demonstrated an increase in A 3 AR expression throughout the progression of kidney injury in both diabetic patients and experimental rat models 10, 11 . The present study consistently showed higher renal A 3 AR protein expression in db/db than in db/m mice. Accordingly, highly expressed A 3 ARs can be a remarkable therapeutic target in halting the progression of DKD. Our present study demonstrated that 12 weeks of treatment with LJ-2698, a species-independent and orally active A 3 AR antagonist, improved kidney function and protected histomorphological changes in db/db mice, which is a T2DM mouse model. LJ-2698 exerted high affinity and selectivity in A 3 AR of both human and murine species, offering its potency to be evaluated in smallanimal models and further developed as a clinical drug 16 . LJ-2698 prevented the progression of diabetic kidney injury in a dose-dependent manner, with the dose of 10 mg/kg showing optimal inhibition in the diabetic kidney milieu. Noticeably, the efficacy of LJ-2698 was not significantly different from losartan in ameliorating diabetic kidney injury.
Under our experimental conditions, administration of an A 3 AR antagonist for 12 weeks did not change renal A 1 AR, A 2b AR, or A 3 AR protein expression levels in db/db mice. Interestingly, renal A 2a AR protein expression was significantly increased in LJ-2698-treated mice. As A 2a AR has been acknowledged to play a protective role in the diabetic kidney 17, 18 , further study is important to elucidate the significant contributions of A 2a AR elevation in protecting kidneys against diabetic injury under A 3 AR antagonism ( Supplementary Figure 1 ).
In the present study, 20-week-old db/db mice exhibited higher blood glucose, HbA1C, and urinary volume than db/ m mice. These biochemical characteristics were not affected by either LJ-2698 or losartan administration. Regarding the role of AR in metabolism, several reports suggested that modulation of insulin secretion and glucose homeostasis were mainly regulated via A 1 AR, A 2a AR, and A 2b AR [19] [20] [21] . A 2a AR was reported to activate brown adipose tissue and recruit beige adipocytes, explaining the improvement in glucose tolerance and leaner body weight in high-fat diet (HFD)-fed mice treated with an A 2a AR agonist 22 .
Despite the fact that LJ-2698 did not alleviate hyperglycemia, it improved kidney function in db/db mice, suggesting its direct renoprotective effects. First, we demonstrated that LJ-2698 at a dose of 10 mg/kg, but not 0.5 or 5 mg/kg, significantly decreased all parameters related to DKD progression, including glomerulosclerosis, albuminuria, inflammation, as well as podocyte and tubular injury. Then, we investigated whether 10 mg/kg LJ- 2698 had a comparable efficacy to losartan, a wellestablished treatment for preventing the progression of DKD in T2DM 23 . Losartan, a drug from the ARB class, has been proved in a large clinical trial to reduce the risk of chronic kidney failure and the doubling of serum creatinine by 25-28% compared to placebo 24 . LJ-2698, which has a different primary target from losartan, showed a comparable reduction in albuminuria, improvement of kidney morphology, and inhibition of podocyte injury to that of losartan. Although another study showed that losartan can protect kidney tubular injury 25 , our study found that only LJ treatment significantly reduced urinary KIM-1, which is a sensitive marker for proximal tubular injury 26 . This discrepancy can be explained by different doses of losartan treatment, animal species, animal models, and parameters used for detecting tubular injury 25 .
Inflammatory cells and cytokines classically play a vital role in fibroblast activation in the development of kidney fibrosis, which is the final outcome of progressive kidney diseases 27 . Our data in mouse proximal tubular cells 15 and podocyte cells (unpublished data) suggested that A 3 AR is activated under stimulation of either pro-fibrotic cytokines (i.e., TGF-β) or diabetic stress, such as high glucose, angiotensin-II, and palmitic acid. Inhibition of A 3 AR by an LJ-compound leads to a significant inhibition in fibrotic signaling in both cell types. Since A 3 AR may also play a role in modulating kidney hemodynamics and inflammation, the effects of A 3 AR antagonism in other kidney cells, such as kidney vasculatures, macrophage, and mesangial cells, should be further investigated.
In the present study, upregulated pro-inflammatory and pro-fibrotic markers in diabetic mice were significantly reduced by either LJ-2698 or losartan treatment. In regard to its mechanism of action, A 3 AR is a member of the GPCR family, which are coupled to Gi-mediated inhibition of adenylyl cyclase, Gq-mediated stimulation of PLC, and mitogen-activated protein kinase (MAPK) signaling pathways 28 . It has been well established that MAPKs, including c-Jun N-terminal kinase (JNK), extracellular signal regulated kinase (ERK) and p38 MAPK, are involved in the progression of kidney injury, which is characterized by increased extracellular matrix accumulation and epithelial to mesenchymal transition leading to kidney fibrosis [29] [30] [31] [32] . Hence, these results suggest that A 3 AR antagonism can halt the progression of kidney fibrosis, partially through inhibition of the MAPK pathway, and remains to be elucidated in future studies.
In addition to the aforementioned results, oxidative stress markers, such as 8-oxo-dG and kidney LPO, were suppressed in both treatment groups. Interestingly, the urinary LPO concentration was significantly reduced by LJ treatment but remained unchanged in the losartan treatment group. Consistent with our findings, other studies with different kidney injury models suggested that losartan treatment could inhibit oxidative stress, as seen from reduction of parameters other than urinary LPO. Those reduced parameters were related to lipid peroxidation and activation of antioxidant enzymes, such as superoxide dismutase, catalase, and glutathione peroxidase [33] [34] [35] .
db/db mice are classically known as a renal lipotoxicity model 36 induced by reduction of lipolysis via fatty acid βoxidation. This utilization defect causes energy depletion that leads to apoptosis, dedifferentiation, eventual fibrosis and chronic kidney disease progression 37 . In the present study, higher renal lipid accumulation was observed in db/db than in db/m mice and was significantly decreased by either LJ-2698 or losartan treatment.
Under our experimental conditions, renal PGC1α, a master regulator of mitochondrial biogenesis, was increased in either LJ-2698-or losartan-treated mice compared to control db/db mice. It is well recognized that PGC1α interacts with transcription factors, such as ERRα, PPAR, NRF1, and NRF2, whose target genes increase mitochondrial biogenesis, oxidative phosphorylation, and fatty acid β-oxidation 38, 39 . In parallel, elevation of PPARα and NRF1 was observed in diabetic mice treated with either LJ-2698 or losartan. The increased PGC1α protein level indirectly implies the improvement of mitochondrial biogenesis, oxidative phosphorylation, and fatty acid βoxidation, as shown by the elevation of TFAM; COX4i1 and Cytb; and CPT1α and MCAD, respectively.
In summary, we are the first to show that LJ-2698, a highly selective and species-independent A 3 AR antagonist, ameliorated diabetic kidney injury in db/db mice. LJ-2698 ameliorated the progression of diabetic kidney injury to the same extent as losartan. Oxidative stress, inflammation, lipid accumulation, albuminuria, glomerulosclerosis, and tubulointerstitial fibrosis were all aggravated in db/db mice and significantly reversed by LJ-2698 treatment. Thus, we suggest that LJ-2698 can be a new treatment option in preventing diabetic kidney progression.
For further insight into the efficacy of LJ-2698, therapeutic effects of delayed treatment with LJ-2698 in DKD should be investigated. Potential effects of LJ-2698 in adipose and cardiac tissues, which are related to modulation of A 3 AR antagonism on metabolism and longterm complication in DKD, should be elucidated. Finally, since LJ-2698 and losartan have different primary targets in protecting the kidneys, it is also imperative to investigate the renoprotective effects of the combination therapy of both drugs in DKD.
